Brought to you by 
Additional round brings $20mm to BiPar Sciences
09 Feb 2009
Executive Summary
Cancer drug developer BiPar Sciences raised $20mm through an additional financing round. Returning investors included Domain Associates, Canaan Partners, Vulcan Capital, PolyTechnos Venture-Partners, Asset Management Co., Quantum Technology Partners, and Lighthouse Capital Partners, which provided venture debt. BiPar will use the proceeds to advance its lead program BSI201 into Phase III trials for breast cancer.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Nonconvertible Debt
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Additional round brings $20mm to BiPar Sciences
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice